Top

Molecular Cancer

Published in:

Open Access 01-12-2017 | Research

Role of the lncRNA ABHD11-AS₁ in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC

Authors: Dan-Dan Wu, Xi Chen, Kai-Xuan Sun, Li-Li Wang, Shuo Chen, Yang Zhao

Published in: Molecular Cancer | Issue 1/2017

Abstract

Background

There is increasing evidence in support of the role of lncRNAs in tumor cell proliferation, differentiation and apoptosis.

Methods

We examined the expression of the lncRNA ABHD11-AS₁ in epithelial ovarian cancer (EOC) tissues and normal ovarian tissues by real-time quantitative PCR (qRT-PCR). After inducing ABHD11-AS₁ downregulation by small interfering RNA (siRNA) or ABHD11-AS₁ overexpression by plasmid transfection, we examined the EOC cell phenotypes and expression of related molecules.

Results

Expression of the lncRNA ABHD11-AS₁ in EOC tissues was higher than that in normal ovarian tissue. It was positively associated with the tumor stage (stage I/II vs. stage III/IV), and it was lower in the well-differentiated group than in the poorly/moderately differentiated group. Overexpression of ABHD11-AS₁ in the ovarian cancer cell lines A2780 and OVCAR3 promoted ovarian cancer cell proliferation, invasion and migration, and inhibited apoptosis. Silencing of ABHD11-AS₁ had the opposite effect. Subcutaneous injection of tumor cells in nude mice showed that ABHD11-AS₁ could significantly promote tumor growth. In addition, intraperitoneal injection of tumor cells in the nude mice resulted in an increase in the metastatic ability of the tumor. Further, overexpression of ABHD11-AS₁ upregulated the expression of RhoC and its downstream molecules P70s6k, MMP2 and BCL-xL. Silencing of ABHD11-AS₁ had the opposite effect. The RNA pull-down assay showed that ABHD11-AS₁ can combine directly with RhoC. Silencing of RhoC was found to inhibit the cancer-promoting effects of lncRNA ABHD11-AS₁. Thus, it seems that RhoC is a major target of the lncRNA ABHD11-AS₁.

Conclusions

This is the first study to demonstrate the role of RhoC in the tumor-promoting effects of the lncRNA ABHD11-AS₁. The present findings shed light on new therapeutic targets for ovarian cancer treatment.

Available only for authorised users

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88.CrossRefPubMed

Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LL, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology. 2016;63:499–511.CrossRefPubMed

Ma Y, Yang Y, Wang F, Moyer MP, Wei Q, Zhang P, et al. Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. Gut. 2016;65:1494–504.CrossRefPubMed

Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2014;65:1140–51.CrossRefPubMed

Fan J, Xing Y, Wen X, Jia R, Ni H, He J, et al. Long non-coding RNA ROR decoys gene-specific histone methylation to promote tumorigenesis. Genome Biol. 2015;16:139.CrossRefPubMedPubMedCentral

Sun M, Kraus WL. From discovery to function: the expanding roles of long non-coding RNAs in physiology and disease. Endocr Rev. 2015;7:er00009999.CrossRef

Schaukowitch K, Kim TK. Emerging epigenetic mechanisms of long non-coding RNAs. Neuroscience. 2014;264:25–38.CrossRefPubMed

Lin X, Yang M, Xia T, Guo J. Increased expression of long noncoding RNA ABHD11-AS1in gastric cancer and its clinical significance. Med Oncol. 2014;31:42.CrossRefPubMed

Yang Y, Shao Y, Zhu M, Li Q, Yang F, Lu X, et al. Using gastric juice lncRNA-ABHD11-AS1 AS a novel type of biomarker in the screening of gastric cancer. Tumour Biol. 2016;37:1183–8.CrossRefPubMed

10.

Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–69.CrossRefPubMed

11.

Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ, Niu ZF. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy. Gynecol Oncol. 2013;130:570–8.CrossRefPubMed

12.

Chen X, Chen S, Xiu YL, Sun KX, Zong ZH, Zhao Y. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. Mol Cancer. 2015;14:31.CrossRefPubMedPubMedCentral

13.

Lozano E, Betson M, Braga VM. Tumor progression: small GTPases and loss of cell-cell adhesion. BioEssays. 2003;25:452–63.CrossRefPubMed

14.

Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.CrossRefPubMed

15.

Rieger C, Huebner D, Temme A, Wirth MP, Fuessel S. Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells. Int J Oncol. 2015;47:1121–30.PubMed

16.

Bahrami-B F, Ataie-Kachoie P, Pourgholami MH, Morris DL. p70 Ribosomal proteinS6 kinase (Rps6kb1): an update. J Clin Pathol. 2014;67:1019–25.CrossRefPubMed

17.

Ip CK, Yung S, Chan TM, Tsao SW, Wong AS. p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation. Oncotarget. 2014;5:9133–49.CrossRefPubMed

18.

Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494–504.CrossRefPubMedPubMedCentral

19.

Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904–14.CrossRefPubMedPubMedCentral

20.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the rosetta stone of a hidden RNA language. Cell. 2011;146:353–8.CrossRefPubMedPubMedCentral

21.

Liu N, Zhang G, Bi F, Pan Y, Xue Y, Shi Y, et al. RhoC is essential for the metastasis of gastric cancer. J Mol Med (Berl). 2007;85:1149–56.CrossRef

22.

Hakem A, Sanchez-Sweatman O, You-Ten A, Duncan G, Wakeham A, Khokha R, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 2005;19:1974–79.

23.

Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol. 2002;160:579–84.CrossRefPubMedPubMedCentral

24.

van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832–8.PubMed

25.

Islam M, Lin G, Brenner JC, Pan Q, Merajver SD, Hou Y, et al. RhoC expression and head and neck cancer metastasis. Mol Cancer Res. 2009;7:1771–80.CrossRefPubMedPubMedCentral

26.

Kleer CG, Teknos TN, Islam M, Marcus B, Lee JS, Pan Q, et al. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res. 2006;12:4485–90.CrossRefPubMed

27.

Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W. Expression of RhoC is associated with metastasis of gastric carcinomas. Pathobiology. 2004;71:19–25.CrossRefPubMed

28.

Wang W, Wu F, Fang F, Tao Y, Yang L. Inhibition of invasion and metastasis of hepatocellular carcinoma cells via targeting RhoC in vitroand in vivo. Clin Cancer Res. 2008;14:6804–12.CrossRefPubMed

29.

Yao H, Dashner EJ, van Golen CM, van Golen KL. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene. 2006;25:2285–96.CrossRefPubMed

30.

Sequeira L, Dubyk CW, Riesenberger TA, Cooper CR, van Golen KL. Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis. Clin Exp Metastasis. 2008;25:569–79.CrossRefPubMed

31.

Faried A, Faried LS, Kimura H, Nakajima M, Sohda M, Miyazaki T, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitroandin vivo. Eur J Cancer. 2006;42:1455–65.CrossRefPubMed

32.

Xia L, Huang W, Tian D, Zhu H, Zhang Y, Hu H, et al. Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma. J Hepatol. 2012;57:600–12.CrossRefPubMed

33.

Liu X, Wang C, Chen Z. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J. 2011;440:23–31.CrossRefPubMedPubMedCentral

34.

Xue G, Zou X, Zhou JY, Sun W, Wu J, Xu JL, et al. Raddeanin a induces human gastric cancer cells apoptosis and inhibits their invasion in vitro. Biochem Biophys Res Commun. 2013;439:196–202.CrossRefPubMed

35.

Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D'Silva N, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014;124:179–87.CrossRefPubMed

36.

Nakabayashi H, Shimizu K. HA1077, a rho kinase inhibitor,suppresses glioma-induced angiogenesis by targeting the rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulatedkinase (MEK/ERK) signal pathways. Cancer Sci. 2011;102:393–9.CrossRefPubMed

Title: Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC
Authors: Dan-Dan Wu
Xi Chen
Kai-Xuan Sun
Li-Li Wang
Shuo Chen
Yang Zhao
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-017-0709-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma

Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma

Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma

The noncoding RNA HOXD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinoma

MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours

ITIH5 mediates epigenetic reprogramming of breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer